PubMed Health⌕ Search

PubMed · 2427182

Intralesional injections.

Abstract

Several types of agents used for intradermal and intralesional injection have been presented along with general discussion of technique and principles of use. We have a great deal of respect for the effectiveness of properly utilized injections in the treatment of various conditions, and we also know that if used improperly, these agents can do more harm than good. For this reason, we caution practitioners to use common sense and to refer to product information and specific sources for additional information before using any of the medications or drugs discussed here. Special attention should be given to systemic absorption and the use of these drugs in infants and children, pregnant and nursing females, and in patients with systemic illness. Each of the agents presented must be evaluated independently and information and experience gathered will aid in the longterm results of their use. We hope this report helps to describe intralesional injections for treatment of some of the more common lesions and that your patients will benefit from this technique.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G L Dockery, R Z Nilson. 1986. Intralesional injections.. https://pubmed.ncbi.nlm.nih.gov/2427182/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗